Erste Asset Management GmbH Acquires 26,000 Shares of Arrowhead Pharmaceuticals, Inc. $ARWR

Erste Asset Management GmbH boosted its holdings in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) by 55.3% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 73,000 shares of the biotechnology company’s stock after purchasing an additional 26,000 shares during the quarter. Erste Asset Management GmbH’s holdings in Arrowhead Pharmaceuticals were worth $2,466,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently made changes to their positions in ARWR. Marex Group plc acquired a new stake in shares of Arrowhead Pharmaceuticals in the second quarter valued at approximately $576,000. Nordea Investment Management AB increased its stake in Arrowhead Pharmaceuticals by 74.5% during the 3rd quarter. Nordea Investment Management AB now owns 372,282 shares of the biotechnology company’s stock worth $12,661,000 after acquiring an additional 158,937 shares during the period. Marshall Wace LLP raised its holdings in Arrowhead Pharmaceuticals by 3,507.8% in the 2nd quarter. Marshall Wace LLP now owns 2,155,998 shares of the biotechnology company’s stock valued at $34,065,000 after acquiring an additional 2,096,238 shares in the last quarter. HBK Sorce Advisory LLC acquired a new position in Arrowhead Pharmaceuticals in the 3rd quarter valued at $2,823,000. Finally, Vanguard Personalized Indexing Management LLC bought a new stake in shares of Arrowhead Pharmaceuticals during the 3rd quarter valued at $287,000. Institutional investors and hedge funds own 62.61% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms recently commented on ARWR. Royal Bank Of Canada boosted their price target on Arrowhead Pharmaceuticals from $52.00 to $80.00 and gave the company an “outperform” rating in a research note on Thursday, December 11th. The Goldman Sachs Group raised their target price on shares of Arrowhead Pharmaceuticals from $50.00 to $85.00 and gave the company a “neutral” rating in a report on Wednesday, January 7th. Weiss Ratings raised shares of Arrowhead Pharmaceuticals from a “sell (d-)” rating to a “hold (c-)” rating in a report on Friday, February 6th. Chardan Capital lifted their price objective on shares of Arrowhead Pharmaceuticals from $60.00 to $80.00 and gave the company a “buy” rating in a research note on Wednesday, January 7th. Finally, HC Wainwright restated a “buy” rating and set a $100.00 price objective on shares of Arrowhead Pharmaceuticals in a research report on Tuesday, February 10th. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and four have issued a Hold rating to the company. According to MarketBeat, Arrowhead Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus price target of $81.67.

Insider Transactions at Arrowhead Pharmaceuticals

In other Arrowhead Pharmaceuticals news, CEO Christopher Richard Anzalone sold 130,000 shares of the company’s stock in a transaction that occurred on Monday, December 15th. The shares were sold at an average price of $68.85, for a total value of $8,950,500.00. Following the completion of the transaction, the chief executive officer directly owned 3,971,255 shares in the company, valued at approximately $273,420,906.75. This represents a 3.17% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider James C. Hamilton sold 40,164 shares of the firm’s stock in a transaction on Monday, January 5th. The shares were sold at an average price of $63.11, for a total transaction of $2,534,750.04. Following the transaction, the insider directly owned 171,958 shares of the company’s stock, valued at $10,852,269.38. The trade was a 18.93% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 502,086 shares of company stock worth $33,109,648. 3.60% of the stock is owned by corporate insiders.

Arrowhead Pharmaceuticals Stock Down 0.2%

Shares of ARWR opened at $63.27 on Friday. Arrowhead Pharmaceuticals, Inc. has a 52 week low of $9.57 and a 52 week high of $76.76. The stock has a market capitalization of $8.86 billion, a price-to-earnings ratio of 41.35 and a beta of 1.21. The company has a debt-to-equity ratio of 0.29, a quick ratio of 3.38 and a current ratio of 3.38. The stock has a fifty day moving average of $66.12 and a 200-day moving average of $48.55.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last issued its quarterly earnings data on Thursday, February 5th. The biotechnology company reported $0.22 earnings per share for the quarter, missing analysts’ consensus estimates of $0.60 by ($0.38). The firm had revenue of $264.03 million for the quarter, compared to the consensus estimate of $225.66 million. Arrowhead Pharmaceuticals had a return on equity of 35.64% and a net margin of 18.54%.The company’s revenue was up 10461.3% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($1.39) EPS. As a group, sell-side analysts anticipate that Arrowhead Pharmaceuticals, Inc. will post -2.42 earnings per share for the current fiscal year.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company’s approach aims to offer durable, targeted treatments across a range of therapeutic areas.

The company’s pipeline includes multiple candidates in various stages of development.